Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.

Hallinen, Taru; Kivelä, Santtu; Soini, Erkki; Harjola, Veli-Pekka; Pesonen, Mari

Hallinen, Taru; Kivelä, Santtu; Soini, Erkki; Harjola, Veli-Pekka; Pesonen, Mari.

Afiliación

Hallinen T; ESiOR Oy, Kuopio, Finland.
Kivelä S; ESiOR Oy, Kuopio, Finland.
Soini E; ESiOR Oy, Kuopio, Finland.
Harjola VP; Emergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
Pesonen M; Boehringer Ingelheim Ky, Helsinki, Finland.

Clinicoecon Outcomes Res ; 15: 1-13, 2023.

Article en En | MEDLINE | ID: mdl-36636485

Palabras clave

cost-utility analysis; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; sodium-glucose cotransporter 2 inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Clinicoecon Outcomes Res Año: 2023 Tipo del documento: Article País de afiliación: Finlandia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google